ClinicalTrials.gg
CompletedNCT01263093Updated Oct 22, 2018Results posted

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

A Phase 1 interventional study of Clopidogrel and LY2216684 in Major Depressive Disorder, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing edivoxetine in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. edivoxetine · Depressive Disorder, Major.

Enrollment
10th of 24
47 · median 29
Started
2010
with 10 others
Phase 1
15 of 24
none open now
Registered
11th of 24
by date
Lead sponsor
24 of 24
Eli Lilly and Company

Among the 24 studies testing edivoxetine in Depressive Disorder, Major, this one is the 10th largest by enrollment, is one of 11 that started in 2010, is one of 15 in phase 1, and was the 11th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 24 studies testing edivoxetine in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

About edivoxetine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing edivoxetine in Depressive Disorder, Major as a file.
02

Study summary

The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected.

Read the detailed description

Clopidogrel is rapidly converted to R-130964 by the enzyme cytochrome P450 2C19 (CYP2C19). Enrollment in the study was limited to participants with specific genotypes of the CYP2C19 gene, including the *1/*1 genotype (CYP2C19 extensive metabolizers) and the *1/*17 or *17/*17 genotypes (CYP2C19 ultra-rapid metabolizers). All primary and secondary objectives were limited to participants with the CYP2C19*1/*1 genotype.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy, as determined by medical history and physical examination.
  • Male participants - Agree to use a reliable method of during the study and for 1 month following the last dose of study drug.
  • Female participants - Women of who test negative for pregnancy at the time of enrollment, have used a reliable method of birth control for 6 weeks prior to administration of study drug, and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; or women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause (at least 1 year without menses or 6 months without menses and a follicle stimulating hormone [FSH] >40 milli-international units per milliliter [mIU/mL]).
  • Have a body weight >50 kilograms (kg).
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator.
  • Have venous access sufficient to allow blood sampling as per the protocol.
  • Have normal blood pressure and pulse rate (sitting position) as determined by the investigator.
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site.
  • Are cytochrome P450 (CYP) 2C19 extensive metabolizers or ultra -rapid metabolizers as determined by genotyping assessment.

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an drug or device or off-label use of a drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have known allergies to LY2216684, clopidogrel, or related compounds.
  • Are persons who have previously completed or withdrawn from this study or any other study investigating LY2216684 within 6 months prior to screening.
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Have a history of or show evidence of significant active neuropsychiatric disease or have a history of suicide attempt or ideation.
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  • Show evidence of (HIV) and/or positive human HIV antibodies.
  • Show evidence of and/or positive hepatitis C antibody.
  • Show evidence of and/or positive hepatitis B surface antigen.
  • Are women with a positive pregnancy test or women who are lactating.
  • Intend to use over-the-counter or prescription medication within 14 days prior to dosing unless deemed acceptable by the investigator and Sponsor's medical monitor, except for influenza vaccinations.
  • Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of CYP2C19 or within 30 days prior to dosing.
  • Have donated blood of more than 500 milliliters (mL) within the last month.
  • Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling to stop alcohol consumption 48 hours prior to check-in until completion of the study (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any participants unwilling to adhere to study caffeine restrictions.
  • Have used any tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment.
  • Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment and during the study.
  • Have a documented or suspected history of glaucoma.
  • History or presence of significant bleeding disorders that is, haematemesis, melanena, severe or recurrent epistaxis, haemoptysis, clinically overt clinical haematuria or intracranial haemorrhage.
  • Participants with a history of gastrointestinal ulcers or haemorrhage.
  • Personal or family history of coagulation or bleeding disorders or reasonable suspicion of vascular malformations, for example, cerebral haemorrhage, aneurysm or premature stroke (cerebrovascular accident \<65 years of age).
  • Self-reported history of increased bleeding from trauma (for example, prolonged bleeding after tooth extraction).
  • History of major surgery within 3 months of screening.
  • Planned surgery within 14 days after the last day of dosing.
  • (INR), prothrombin time (PT), activated partial thromboplastin time (APTT) above the normal reference range or count below the normal reference range at screening.
  • Positive fecal occult blood examination at screening.
  • abnormality in fundoscopic or petechiae examination.
  • Consumption of aspirin, other non-steroidal anti-inflammatory drugs or other drugs known to affect platelet function within 21 days prior to dosing.
  • Participants determined to be unsuitable by the investigator for any reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Clopidogrel First, Then LY2216684 + Clopidogrel

    Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1). Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2). There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2.

    Drug: Clopidogrel · Drug: LY2216684

  • Experimental
    LY2216684 + Clopidogrel First, Then Clopidogrel

    Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2). Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1). There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2.

    Drug: Clopidogrel · Drug: LY2216684

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)

    R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.

    Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose

  2. Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)

    R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed AUC0-tlast was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.

    Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose

  3. Pharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax)

    R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed Cmax was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.

    Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose

  4. Pharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax)

    R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.

    Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose

Secondary outcomes

  1. Percentage Inhibition of Platelet Aggregation

    Blood samples for the measurement of platelet aggregation using a point-of-care device, Accumetrics VerifyNow™ P2Y12 (VN-P2Y12), were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Device-reported percent inhibition of VN-P2Y12 (IPRU) is presented.

    Time frame: predose and 2, 4, and 24 hours postdose

07

Results

Posted Oct 22, 2018

Participant flow

Period 1
Participant flow — Period 1
MilestoneClopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then Clopidogrel
Started2423
Completed2423
Not completed00
Washout
Participant flow — Washout
MilestoneClopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then Clopidogrel
Started2423
Completed2323
Not completed10
Withdrew: Physician decision10
Period 2
Participant flow — Period 2
MilestoneClopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then Clopidogrel
Started2323
Completed2223
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryPharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)

R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.

Time frame:
predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · hours*nanograms/milliliters (h*ng/mL)
Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)
hours*nanograms/milliliters (h*ng/mL)ClopidogrelLY2216684 + Clopidogrel
Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)61.8 ± 5055.3 ± 44
PrimaryPharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)

R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed AUC0-tlast was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.

Time frame:
predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · hours*nanograms/milliliters (h*ng/mL)
Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)
hours*nanograms/milliliters (h*ng/mL)ClopidogrelLY2216684 + Clopidogrel
Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)60.5 ± 4546.9 ± 41
Statistical analysis
  • Clopidogrel vs LY2216684 + Clopidogrel · Mixed Models Analysis · Ratio of geometric least squares means: 0.77 · 90% CI 0.72 to 0.83Statistical inference was made using the test treatment of LY2216684 + clopidogrel and the reference treatment of clopidogrel alone.
PrimaryPharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax)

R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed Cmax was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.

Time frame:
predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax)
nanograms/milliliter (ng/mL)ClopidogrelLY2216684 + Clopidogrel
Pharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax)37.6 ± 5622.7 ± 53
Statistical analysis
  • Clopidogrel vs LY2216684 + Clopidogrel · Mixed Models Analysis · Ratio of geometric least squares means: 0.59 · 90% CI 0.53 to 0.67Statistical inference was made using the test treatment of LY2216684 + clopidogrel and the reference treatment of clopidogrel alone.
SecondaryPercentage Inhibition of Platelet Aggregation

Blood samples for the measurement of platelet aggregation using a point-of-care device, Accumetrics VerifyNow™ P2Y12 (VN-P2Y12), were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Device-reported percent inhibition of VN-P2Y12 (IPRU) is presented.

Time frame:
predose and 2, 4, and 24 hours postdose
Reported as:
Mean · IPRU
Percentage Inhibition of Platelet Aggregation
IPRUClopidogrelLY2216684 + Clopidogrel
Predose1.7 ± 3.21.4 ± 3.2
2 Hours Postdose16.0 ± 20.37.6 ± 12.3
4 Hours Postdose30.4 ± 21.814.0 ± 16.6
24 Hours Postdose25.1 ± 21.114.3 ± 17.5
PrimaryPharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax)

R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.

Time frame:
predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Reported as:
Median · hours
Pharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax)
hoursClopidogrelLY2216684 + Clopidogrel
Pharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax)1.50 (1.00 to 2.07)1.50 (0.50 to 4.00)
Statistical analysis
  • Clopidogrel vs LY2216684 + Clopidogrel · Wilcoxon (Mann-Whitney) · p = 0.3303 · Median of paired differences: 0.00 · 90% CI 0.00 to 0.25

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clopidogrel—0/47 (0%)12/47 (25.5%)
LY2216684—0/46 (0%)19/46 (41.3%)
LY2216684 + Clopidogrel—0/45 (0%)11/45 (24.4%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventClopidogrelLY2216684LY2216684 + Clopidogrel
NauseaGastrointestinal disorders1/477/462/45
SomnolenceNervous system disorders0/477/460/45
HeadacheNervous system disorders6/471/461/45
Urinary hesitationRenal and urinary disorders0/474/460/45
InsomniaPsychiatric disorders0/473/463/45
RashSkin and subcutaneous tissue disorders0/471/463/45
Abdominal painGastrointestinal disorders0/473/460/45
VomitingGastrointestinal disorders0/473/460/45
CoughRespiratory, thoracic and mediastinal disorders3/470/460/45
ChillsGeneral disorders2/471/462/45

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Clopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then ClopidogrelTotal
Mean40.7 ± 11.244.5 ± 11.542.5 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Clopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then ClopidogrelTotal
Female101222
Male141125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Clopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then ClopidogrelTotal
Hispanic or Latino161228
Not Hispanic or Latino81119
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Clopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then ClopidogrelTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American459
White201838
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Clopidogrel First, Then LY2216684 + ClopidogrelLY2216684 + Clopidogrel First, Then ClopidogrelTotal
United States242347
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 7 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2010
First posted
Dec 20, 2010
Start
Dec 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Oct 22, 2018
Last update
Oct 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01263093
Responsible party
Sponsor
First posted
Dec 20, 2010
Start date
Dec 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Oct 22, 2018
Last update
Oct 22, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clopidogrel · Edivoxetine

Start the discussion